Drug combo trial for first treatment of advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of an immunotherapy drug (PD1/TGFβ), another targeted drug (SHR2554 or apatinib), and chemotherapy for people who have not yet been treated for advanced stomach cancer. The goal is to see if this combination works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced or metastatic stomach or gastroesophageal junction cancer that cannot be removed with surgery.
- You must not have had any previous treatment for advanced disease, though prior chemotherapy before surgery is allowed if the cancer returned more than 6 months later.
- You must be in generally good health, able to perform daily activities (ECOG score 0-2), and have adequate organ function (like kidney, liver, and blood counts).
- You cannot have HER2-positive cancer, active heart disease, bleeding problems, autoimmune diseases, or active infections like hepatitis or tuberculosis.
- You must agree to use effective birth control during the study and for 90 days after, if you or your partner could become pregnant.
- You must be willing to provide blood and tumor tissue samples and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of medications (IBI363 plus bevacizumab, with or without nab-paclitaxel) for people with advanced stomach cancer that has progressed after first-line treatment. The goal is to see if this combination can shrink tumors or slow cancer growth better than existing options.
This study tests a new combination of drugs (apatinib, nab-paclitaxel, and possibly adebrelimab) for advanced stomach or gastroesophageal junction cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests a new combination of three drugs for stomach cancer that has progressed after initial immunotherapy. It aims to see if this combo can shrink tumors or slow cancer growth, potentially offering a new option for patients like you.
This trial tests a new combination of an anti-HER2 drug (SHR-A1811) plus chemotherapy and an immunotherapy (adebrelimab) for people with untreated advanced stomach cancer. It aims to see if this combination works better than standard treatment.
This trial tests a new immunotherapy drug (SHR-1701) combined with chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen (peritoneal metastasis) but not to other organs like the liver or lungs. The goal is to see if this combination can help shrink or control the cancer before any surgery.
This trial tests a combination of new drugs (SHR-1701, Rivoceranib, and possibly SHR-2554) for people with advanced stomach cancer whose disease has continued to grow after immunotherapy. It aims to find a better treatment option for those who have not had success with standard therapy.
Hear when a new Advanced Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.